Becton Dickinson (BDX) Q2 2026 Earnings Transcript

Becton Dickinson reported Q2 revenue of $4.7 billion, up 2.6%, with adjusted EPS of $2.90 beating expectations and full-year EPS guidance raised to $12.52-$12.72. Adjusted operating margin held at 24.2% and free cash flow was $1.1 billion YTD, while the company returned $2.3 billion to shareholders and reiterated a 2.5x long-term leverage target. Offsetting positives include a 90 bps gross margin decline from tariffs, a voluntary U.S. ship hold on ChloraPrep/PurPrep after an FDA warning letter, and ongoing Alaris, vaccine, and China headwinds.

Analysis

BDX is at an inflection where the market should care less about the current low-single-digit headline and more about mix and operating leverage. The important second-order effect is that the company is quietly re-rating itself from a “defensive medtech compounder” into a higher-quality cash generator: share repurchases are now the primary capital return lever, leverage is trending down, and the portfolio is increasingly weighted to higher-margin platforms that are still early in their commercial ramp. That combination can support multiple expansion even before revenue visibly reaccelerates.

The bigger earnings setup is that the near-term noise is mostly self-inflicted and time-bound. Alaris, vaccines, and China are depressing growth now, but the real issue is whether investors are underestimating the 2027 reset when the Alaris compare becomes less punitive and the company’s underlying 5%ish organic base can show through. If management executes on the current launch cadence, the market may be too slow to credit the revenue bridge from “mid-single-digit core + mix shift + productivity” to durable mid-single-digit companywide growth.

The main risk is not demand—it’s execution drag from regulatory and remediation events interacting with margin inputs. The ChloraPrep/PurPrep hold is likely manageable in dollars, but it creates a perception overhang around quality systems just as BD is asking investors to pay for operating excellence; any extension beyond a few weeks would matter more to sentiment than to near-term EPS. Separately, tariffs are already compressing gross margin, so if resin/oil or pricing doesn’t cooperate into FY27, the stock could de-rate despite the buyback story.

Consensus may be missing that this is increasingly a capital allocation story with an embedded operating turnaround, not just a modest-growth medtech name. At current valuation, aggressive buybacks may be more accretive than small M&A, so the bull case is less about one blockbuster product and more about compounding per-share value while the mix improves. That argues for owning the stock through noise, but using any regulatory-driven weakness as the better entry point rather than chasing strength.

Key Decisions for Investors

• Long BDX on weakness over the next 1-3 weeks: use any selloff tied to the ChloraPrep/PurPrep hold as an entry, since the issue is likely more sentiment than earnings power; target a 6-12 month hold for the buyback/mix-shift thesis.
• Pair trade: long BDX / short WAT for 3-6 months — BDX has clearer self-help via buybacks, productivity, and portfolio mix, while WAT is more exposed to capital spending sensitivity and less direct per-share accretion.
• Sell cash-secured puts on BDX 10-15% below spot with 2-3 month tenor if implied vol spikes on the FDA headline; structure captures premium while monetizing what looks like a bounded operational issue.
• Add a calendar alert for FY27 guidance reset catalysts — if Alaris headwind visibility peaks and share gains hold, consider adding to BDX ahead of the next earnings cycle; upside comes from multiple re-rating, not just EPS beats.
• Avoid shorting BDX solely on gross margin pressure: tariffs are visible and already discounted, while the company has multiple offsets; downside is more likely to be time-based disappointment than a fundamental earnings break.